C7118

Sigma-Aldrich

Cefdinir

≥97.0% (HPLC)

Sinônimo(s):
BMY-28488, syn-7-[2-(2-amino-4-thiazolyl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid, FK-482, [6R-[6α-7beta(Z)]]-7-[[(2-Amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Empirical Formula (Hill Notation):
C14H13N5O5S2
Número CAS:
Peso molecular:
395.41
NACRES:
NA.85

Nível de qualidade

200

teor

≥97.0% (HPLC)

forma

powder or crystals

pKa 

9.70

pf

170 °C

Modo de ação

cell wall synthesis | interferes

espectro de atividade do antibiótico

Gram-negative bacteria
Gram-positive bacteria

temperatura de armazenamento

room temp

InChI

1S/C14H13N5O5S2/c1-2-5-3-25-12-8(11(21)19(12)9(5)13(22)23)17-10(20)7(18-24)6-4-26-14(15)16-6/h2,4,8,12,24H,1,3H2,(H2,15,16)(H,17,20)(H,22,23)/b18-7-/t8-,12-/m1/s1

InChI key

RTXOFQZKPXMALH-GHXIOONMSA-N

Procurando produtos similares? Visit Guia de comparação de produtos

Categorias relacionadas

Descrição geral

Chemical structure: ß-lactam

Aplicação

Cefdinir was used to study bacterial infections caused by Staphylococcus aureus and Neisseria gonorrhoeae and the horizontal transfer of the ftsI gene in H. influenzae.
An advanced-generation, cephalosporin antibiotic. Used for its excellent and well balanced antibacterial activities against gram-positive and gram-negative bacteria.

Ações bioquímicas/fisiológicas

Cefdinir is an advanced generation amino-2-thiazolyl cephalosporin effective against Gram-positive and Gram-negative bacteria. It acts by disrupting the synthesis of the peptidoglycan layer of bacterial cell walls. It is also known to inhibit human neutrophil myeloperoxidases.

Outras notas

Keep container tightly closed in a dry and well-ventilated place. Keep in a dry place.

RIDADR

NONH for all modes of transport

WGK Alemanha

WGK 3

Ponto de fulgor (ºF)

Not applicable

Ponto de fulgor (ºC)

Not applicable

Certificado de análise
Certificado de origem
Visual diagnosis: four infants who have red, "bloody" stools.
Jill Lowers et al.
Pediatrics in review, 30(4), 146-149 (2009-04-03)
D R Guay
The Annals of pharmacotherapy, 34(12), 1469-1477 (2001-01-06)
To review the antimicrobial activity, pharmacokinetics, clinical efficacy, and tolerability of cefdinir, an expanded-spectrum oral cephalosporin. Literature was identified by a MEDLINE search (January 1983-November 1999) of the medical literature, review of English-language literature and bibliographies of these articles, and...
H Akiyama et al.
The Journal of antimicrobial chemotherapy, 48(4), 487-491 (2001-10-03)
We examined the antibacterial action of several tannins on plasma coagulation by Staphylococcus aureus and the effect of conventional chemotherapy combined with tannic acid below the MIC. Coagulation was inhibited in plasma containing tannic acid (100 mg/L), gallic acid (5000...
Junsung Park et al.
International journal of pharmaceutics, 396(1-2), 239-245 (2010-07-06)
The aim of this study was to investigate the effects of micronization and amorphorization of cefdinir on solubility and dissolution rate. The amorphous samples were prepared by spray-drying (SD) and supercritical anti-solvent (SAS) process, respectively and their amorphous natures were...
Janet R Casey et al.
Drugs, 72(15), 1991-1997 (2012-10-09)
10 days of amoxicillin/clavulanic acid high dose and 5 days of cefdinir have been the preferred first- or second-line antibiotics for treatment of children with acute otitis media (AOM) since 2004, as recommended by the American Academy of Pediatrics in...

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica

Redes sociais

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Pesquisa. Desenvolvimento. Produção.

Somos um fornecedor global líder para o setor de ciências biológicas, com soluções e serviços para pesquisa, desenvolvimento e produção de biotecnologia, além de produção e desenvolvimento de terapias farmacológicas com medicamentos.

© 2021 Merck KGaA, Darmstadt, Alemanha e/ou suas filiais. Todos os direitos reservados.

A reprodução não autorizada de quaisquer materiais deste site é estritamente proibida.